Stockscreener 앱 받기
34.75
2.86%
0.965
시간 외 거래:
34.75
Tyra Biosciences Inc 주식(TYRA)의 최신 뉴스
TYRA SEC FilingsTyra Biosciences, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Tyra Biosciences faces earnings test ahead of key trial data By Investing.com - Investing.com Canada
Tyra Biosciences faces earnings test ahead of key trial data - Investing.com UK
Tyra Biosciences, Inc. (NASDAQ:TYRA) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Guggenheim initiates coverage of Tyra Biosciences (TYRA) with buy recommendation - MSN
Does Tyra Biosciences (TYRA) Board Refresh and Dabogratinib Spotlight Reframe Its Pipeline Credibility? - Sahm
Guggenheim Securities Issues Buy Rating for Tyra Biosciences - HarianBasis.co
Canaan reports 750,000 shares in Tyra Biosciences (NASDAQ: TYRA) - Stock Titan
Guggenheim Starts Tyra Biosciences, Inc. (TYRA) at Buy on Strength of Lead Drug Dabogratinib - Yahoo Finance
Understanding the Setup: (TYRA) and Scalable Risk - Stock Traders Daily
Top 10 AI-Powered Biotech Stocks to Buy Right Now - Insider Monkey
Tyra Biosciences (TYRA) Stock: Entry Strategy Overview | Q4 2025: EPS Misses EstimatesCommunity Buy Signals - Cổng thông tin điện tử tỉnh Tây Ninh
44,400 Tyra Biosciences (TYRA) stock options granted to director Dable - Stock Titan
Tyra Biosciences (TYRA) director Dable Habib J files Form 3 showing no share ownership - Stock Titan
William Blair Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating - 富途牛牛
Tyra Biosciences Announces Appointment of Habib Dable to its Board of Directors - marketscreener.com
Tyra Biosciences adds Habib Dable to board of directors By Investing.com - Investing.com India
Yuliya Rueb Net Worth (2026) - GuruFocus
Tyra Biosciences, Inc. ($TYRA) CEO 2025 Pay Revealed - Quiver Quantitative
Cantor Fitzgerald reiterates Tyra Biosciences stock rating By Investing.com - Investing.com South Africa
Cantor Fitzgerald reiterates Tyra Biosciences stock rating - Investing.com
Tyra Biosciences appoints Habib J. Dable to board of directors By Investing.com - Investing.com Australia
Tyra Biosciences appoints Habib J. Dable to board of directors - Investing.com
Tyra Bioscience Expands Board, Appoints New Independent Director - TipRanks
Tyra Biosciences adds Habib Dable to board of directors - Investing.com
[ARS] Tyra Biosciences, Inc. SEC Filing - Stock Titan
Tyra Biosciences (TYRA) details 2026 virtual meeting, director votes and auditor - Stock Titan
Ty appoints Habib J. Dable to Board as Class II director - TradingView
Habib Dable joins Tyra Biosciences (NASDAQ: TYRA) board as Class II director - Stock Titan
Tyra Biosciences, Inc. (TYRA) Stock Analysis: Unveiling a 45.89% Potential Upside in Biotech Innovation - DirectorsTalk Interviews
Tyra Biosciences Advances Dabogratinib Trial in Niche Urothelial Cancer: What Investors Should Watch - TipRanks
CCORF Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Maintains Target Price $50 - 富途牛牛
Tyra Biosciences (NASDAQ:TYRA) Stock Rating Upgraded by Guggenheim - MarketBeat
TYRA Initiates Coverage On by Guggenheim -- Price Target Announced at $54.00 - GuruFocus
This Tyra Biosciences Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Guggenheim Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Maintains Target Price $54 - 富途牛牛
Guggenheim Initiates Tyra Bioscience at Buy With $54 Price Target - marketscreener.com
Guggenheim Initiates TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Announces Target Price $54 - 富途牛牛
TYRA (Nasdaq) Form 144: Director reports two 8,000-share transactions - Stock Titan
The Technical Signals Behind (TYRA) That Institutions Follow - Stock Traders Daily
Growth Stocks To Watch Today – April 10th - Defense World
JPMorgan Chase & Co. Trims Position in Tyra Biosciences, Inc. $TYRA - MarketBeat
IPO Launch: Is Tyra Biosciences Incs ROE strong enoughEntry Point & Precise Swing Trade Alerts - baoquankhu1.vn
FMR LLC holds 14.4% of Tyra Biosciences (NASDAQ: TYRA) - Stock Titan
Tyra Biosciences (NASDAQ:TYRA) Now Covered by Canaccord Genuity Group - Defense World
Canaccord Genuity Group Begins Coverage on Tyra Biosciences (NASDAQ:TYRA) - MarketBeat
Canaccord Genuity Initiates Tyra Bioscience at Buy With $50 Price Target - marketscreener.com
CCORF Initiates TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Announces Target Price $50 - 富途牛牛
Is Tyra Biosciences (TYRA) Stock a Good Buy in 2026 | Price at $38.93, Down 1.72%Investment Signal Network - Xã Thanh Hà
Growth Stocks To Watch Now – April 3rd - Defense World
3.67%
자본화:
|
볼륨(24시간):